Aeglea Biotherapeutics effects 1-for-25 reverse stock split and reduces authorized shares to 20M

Spyre Therapeutics, Inc.

Reverse stock split at 1-for-25 ratio effective Sept 8, 2023; no fractional shares issued; cash in lieu.
Authorized common shares reduced from 500M to 20M.
Proportional adjustments to Series A preferred conversion, outstanding warrants, and equity awards.
Corporate presentation: adjusted total capitalization ~47.7M shares as-converted as of June 22, 2023.
2022 net loss per share restated to $(24.86) on weighted-average shares of 3.37M post-split.

item 3.03 item 5.03 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Spyre Therapeutics, Inc.: Filed Certificate of Amendment to Restated Certificate of Incorporation to effect a 1-for-25 reverse stock split and reduction of authorized shares from 500,000,000 to 20,000,000 (effective 2023-09-08).

Change: charter amendment
Effective: 2023-09-08

Exact text from the filing

To effect the Reverse Stock Split and the Authorized Shares Reduction, on September 7, 2023, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Amendment”).

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-231646

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.